Physician profile
Kalust Ucar
NPI 1710912175
$7,042.91
in general payments reported to CMS, 2019-2025
31 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,332 · 2020: $676 · 2021: $1,657 · 2023: $125 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $3,415.00 | 2019 | |
| Astellas Pharma US INC | $669.14 | 2019-2025 | Xospata |
| Amgen INC. | $369.10 | 2019-2021 | |
| Pfizer INC. | $314.55 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $210.44 | 2021 | |
| Janssen Biotech, INC. | $198.74 | 2019-2020 | |
| Incyte Corporation | $160.28 | 2021-2023 | Monjuvi |
| Merck Sharp & Dohme LLC | $146.25 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.80 | 2019-2021 | |
| Daiichi Sankyo INC. | $126.60 | 2020-2021 | |
| Glaxosmithkline, LLC. | $122.47 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $121.78 | 2020 | |
| Agios Pharmaceuticals, INC. | $113.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.67 | 2021 | |
| Eisai INC. | $100.31 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $97.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.93 | 2021 | |
| Lilly USA, LLC | $78.64 | 2020-2021 | |
| Genzyme Corporation | $74.45 | 2021 | |
| Genentech USA, INC. | $72.09 | 2019-2021 | |
| Kite Pharma, INC. | $62.91 | 2021 | |
| Blueprint Medicines Corporation | $50.29 | 2021 | |
| Puma Biotechnology, INC. | $35.84 | 2021 | |
| Emd Serono, INC. | $35.82 | 2021 | |
| Seagen INC. | $26.41 | 2020-2021 | |
| Acceleron Pharma, INC. | $23.99 | 2021 | |
| Myovant Sciences INC. | $23.99 | 2021 | |
| Organon LLC | $20.92 | 2021 | |
| Gilead Sciences, INC. | $20.53 | 2019 | |
| Deciphera Pharmaceuticals INC. | $14.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalust Ucar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.